Which factors account for renal stone formation in cystic fibrosis?

2003 ◽  
Vol 59 (03) ◽  
pp. 160-163 ◽  
Author(s):  
R. von der Heiden ◽  
A.P.G. Balestra ◽  
M.G. Bianchetti ◽  
C. Casaulta Aebischer ◽  
P.E. Mullis ◽  
...  
2002 ◽  
Vol 140 (1) ◽  
pp. 103-109 ◽  
Author(s):  
Hansjosef Böhles ◽  
Boris Gebhardt ◽  
Thomas Beeg ◽  
Adrian C. Sewell ◽  
Eivind Solem ◽  
...  

Urolithiasis ◽  
1981 ◽  
pp. 89-92 ◽  
Author(s):  
S. Ljunghall ◽  
B. G. Danielson ◽  
G. Johansson ◽  
L. Wibell

2011 ◽  
Vol 10 (2) ◽  
pp. 228
Author(s):  
K. Taguchi ◽  
A. Okada ◽  
Y. Fujii ◽  
K. Niimi ◽  
T. Kobayashi ◽  
...  
Keyword(s):  

1994 ◽  
Vol 86 (3) ◽  
pp. 239-243 ◽  
Author(s):  
Bruno Baggio ◽  
Giovanni Gambaro ◽  
Francesco Marchini ◽  
Massimo Vincenti ◽  
Giulio Ceolotto ◽  
...  

1. Anomalous transmembrane anion transport has been observed in erythrocytes of patients with idiopathic calcium nephrolithiasis. 2. To verify whether cation transport is also abnormal, we investigated the frusemide-sensitive Na+ efflux from Na+-loaded erythrocytes and the natriuretic response to acute intravenous frusemide administration in calcium oxalate renal stone formers. 3. Frusemide administration induced a statistically significant smaller increase in the fractional excretion of Na+ in patients than in control subjects. Abnormal kinetic properties of erythrocyte Na+-K+-2Cl− co-transport were observed in approximately 60% of stone formers. The Km for Na+ of Na+-K+-2Cl− co-transport correlated with urinary Ca2+ excretion. 4. The abnormal kinetic properties of Na+-K+-2Cl− co-transport may be relevant for stone formation, hampering renal Ca2+ reabsorption in the distal nephron and determining critical physicochemical conditions for calcium/oxalate crystallization.


Nephron ◽  
1993 ◽  
Vol 65 (1) ◽  
pp. 77-81 ◽  
Author(s):  
F. Grases ◽  
A. Costa-Bauzá ◽  
J.G. March ◽  
O. Söhnel
Keyword(s):  

2011 ◽  
Vol 37 (2) ◽  
pp. 259-267 ◽  
Author(s):  
Ibrahim F. Ghalayini ◽  
Mohammed A. Al-Ghazo ◽  
Mohammad N. A. Harfeil

2017 ◽  
Vol 32 (suppl_3) ◽  
pp. iii432-iii432
Author(s):  
Thomas Ernandez ◽  
Catherine Stoermann-Chopard ◽  
Minoa Jung ◽  
William Robertson ◽  
Pierre-Yves Martin ◽  
...  

Nutrients ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 1069
Author(s):  
Allen L. Rodgers ◽  
Roswitha Siener

In the pathogenesis of hypercalciuria and hyperoxaluria, n-6 polyunsaturated fatty acids (PUFAs) have been implicated by virtue of their metabolic links with arachidonic acid (AA) and prostaglandin PGE2. Studies have also shown that n-3 PUFAs, particularly those in fish oil—eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)—can serve as competitive substrates for AA in the n-6 series and can be incorporated into cell membrane phospholipids in the latter’s place, thereby reducing urinary excretions of calcium and oxalate. The present review interrogates several different types of study which address the question of the potential roles played by dietary PUFAs in modulating stone formation. Included among these are human trials that have investigated the effects of dietary PUFA interventions. We identified 16 such trials. Besides fish oil (EPA+DHA), other supplements such as evening primrose oil containing n-6 FAs linoleic acid (LA) and γ-linolenic acid (GLA) were tested. Urinary excretion of calcium or oxalate or both decreased in most trials. However, these decreases were most prominent in the fish oil trials. We recommend the administration of fish oil containing EPA and DHA in the management of calcium oxalate urolithiasis.


Sign in / Sign up

Export Citation Format

Share Document